These results highlight the role of PXR in prostate cancer cell response to targeted therapies and also reveal drug-specific effects that might be inherent to the chemical properties of the inhibitor itself and/or a difference in the metabolic pathways that are triggered in cancer cells. This evidence concerns the gene NR1I2 and Familial prostate cancer.